Dabigatran etexilate: A novel oral thrombin inhibitor for thromboembolic disease;Etexilato de Dabigatrán: Un Novedoso Inhibidor de Trombina Oral para Enfermedades Tromboembólicas

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages 603-614

  Bovio, Jessica A ^a   Smith, Steven M ^b   Gums, John G ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Department of Community Health and Family Medicine ^*  (United States)

^c Director of Clinical Research in Family Medicine   (United States)

Author keywords

Anticoagulant; Atrial fibrillation; Bibr 1048; Dabigatran etexilate; Direct thrombin inhibitor; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; DABIGATRAN ETEXILATE; DIGOXIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; THROMBIN; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; CARDIOEMBOLIC STROKE; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EMBOLISM; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; NAUSEA; PATIENT COUNSELING; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM; VOMITING;

ANTITHROMBIN PROTEINS; BENZIMIDAZOLES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; OFF-LABEL USE; PYRIDINES; THROMBIN; THROMBOEMBOLISM;

EID: 79957600897     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P644     Document Type: Article

References (40)

1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 suppl): 454S-545S. Erratum: Chest 2008;134:892. DOI 10.1378/chest.08-0658
2. Geerts WH, Bergqvist D, Pineo GF, et al.; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 suppl):381S-453S. DOI 10.1378/chest.08-0656
3. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(23 suppl 1):I4-8.
4. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-2.
5. Singer DE, Albers GW, Dalen JE, et al.; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 suppl):546S-592S. DOI 10.1378/chest.08-0678
6. Becattini C, Lignani A, Agnelli G. New anticoagulants for the prevention of venous thromboembolism. Drug Des Devel Ther 2010;4:49-60.
7. Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 2008;14:1152-75.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
9. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85. DOI 10.1111/j.1538-7836.2007.02748.x
10. Eriksson BI, Dahl OE, Rosencher N, et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56.
11. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9. DOI 10.1016/j.arth.2008.01.132
12. Schulman S, Kearon C, Kakkar AK, et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
13. EMEA: Pradaxa EPAR. Product information; 2010 March 18. www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/ human/000829/WC500041059.pdf (accessed 2010 Sep 21).
14. Health Canada: Pradax product monograph; 2010 November 3. webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code= (accessed 2010 Nov 5).
15. FDA: Pradaxa Label. Package insert; 2010 October 19. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.p df (accessed 2010 Nov 5).
16. FDA: Cardiovascular and Renal Drugs Advisory Committee: Food and Drug Administration; 2010 September 20. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drug s/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226011.pdf (accessed 2010 Nov 5).
17. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005;106:2605-12.
18. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008;28:1354-73.
19. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68. DOI 10.2165/11318170-000000000-00000
20. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.Thromb Haemost 2010;103:1116-27. DOI 10.1160/TH09-11-0758
21. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115:15-20. DOI 10.1182/blood-2009-09-241851
22. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45:555-563. DOI10.1177/0091270005274550
23. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22. DOI 10.2165/0003088-200948010-00001
24. Connolly SJ, Pogue J, Eikelboom J, et al.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37. DOI 10.1161/CIRCULATIONAHA.107.750000
25. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-39.
26. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66. DOI 10.1378/chest.129.5.1155
27. Wallentin L, Yusuf S, Ezekowitz MD, et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83. DOI 10.1016/S0140-6736(10)61194-4
28. Eriksson BI, Dahl OE, Huo MH, et al.; for the RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, doubleblind, non-inferiority trial. Thromb Haemost 2011;105:721-9.
29. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
30. HC, Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006;21:279-93. DOI 10.1159/000091265
31. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs lowmolecular- weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-9. DOI10.1001/jama.293.6.681
32. Lip GYH, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010;123:785-9.
33. Thiel DV, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009;15:389-94. DOI 10.1177/1076029609340163
34. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
35. Micromedex Healthcare Series. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. (accessed 2011 Apr 23).
36. Chambers S, Chadda S, Plumb JM. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. Int J Lab Hematol 2010;32:427-442.
37. Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med 2000;1:19-21.
38. Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements; 2011 March 31. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedica lProducts/ucm249005.htm (accessed 2011 Apr 14).
39. Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin 2008;26:169-87.
40. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology 2010;113:726-745.